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ABSTRACT
The oncogene BMI1 encodes a polycomb group
transcription factor that is required for embryonic
development and self-renewal of stem cells. Despite
these important functions little is known about the
regulation of BMI1 expression. A cDNA microarray
based search for target genes of E2F-1 in neuro-
blastoma cells expressing a 4-OHT-regulated E2F-1-
ER fusion protein identified many hitherto unknown
E2F-1 regulated genes. A total of 10% of these genes,
including BMI1, encode proteins that function
primarily in the regulation of gene expression. The
BMI1 promoter contains a putative E2F binding
site that was required for the activation of a BMI1
promoter-dependent reporter construct by E2F-1.
Chromatin immunoprecipitation revealed 4-OHT-
dependent binding of E2F-1-ER and binding of
endogenous E2F-1 to the BMI1 promoter in tumor
cells. We have previously shown activation of the
oncogene MYCN by E2F. Thus, in neuroblastomas
deregulated E2F-1 can activate two oncogenes,
MYCN and BMI1 that are known to co-operate in
tumor formation. Consistent with a role of Bmi1
in neuroblastoma tumorigenesis we found strong
Bmi1 expression in primary neuroblastomas. Our
results reveal a novel link between E2F and poly-
comb transcription factors and suggest a role of
Bmi1 in neuroblastomas.
INTRODUCTION
The Bmi1 protein is a member of the polycomb group (PcG)
proteins. PcG proteins form multiprotein complexes that func-
tion as transcriptional repressors [for a review see (1)]. Several
distinct PcG complexes have been described (2,3). One of
these, termed polycomb repressive complex 2 (PRC2), con-
tains the PcG group proteins Ezh2 and Eed. The core of
the other complex, termed polycomb repressive complex 1
(PRC1), in Drosophila contains the Bmi1-homologous protein
Psc (posterior sex combs), Ph (polyhomeotic), Pc (polycomb)
and Ring-1 (4,5). The corresponding complex in human cells,
hPRC, consists of the orthologous set of proteins (6). The two
different PcG complexes are functionally redundant in the
control of HOX gene expression during embryonic develop-
ment but act antagonistically on the proliferation of hema-
topoietic cells (7).
Several lines of evidence implicate Bmi1 in tumorigenesis.
Firstly, Bmi1 cooperates with c-Myc in the generation of
lymphomas in double transgenic mice (8,9). Secondly,
Bmi1 blocks senescence and immortalizes mouse embryo
ﬁbroblasts, although not human ﬁbroblasts, and in combina-
tion with an activated H-ras gene leads to neoplastic trans-
formation (10). These oncogenic functions depend on the
ability of Bmi1 to repress the INK4A-locus, which encodes
the tumor suppressor proteins p16Ink4a and p14Arf. Thirdly,
the BMI1 gene is ampliﬁed in certain mantle cell lymphomas
and is overexpressed in a subset of non-small cell lung cancer,
colorectal carcinomas, multiple myelomas and medullo-
blastomas, but not glioblastomas (11–15). Fourthly, the trans-
formation of human hematopoietic progenitor cells by the
oncogenic fusion protein E2a-Pbx1 requires Bmi1 (16).
Indeed, based on a list of genes differentially expressed in
a mouse model of metastatic prostate cancer on a wild-type
and bmi1-deﬁcient genetic background a gene signature was
recently identiﬁed that may predict response to therapy and
survival in multiple types of cancer (17).
The oncogenic activity of Bmi1 may be linked to another
fundamental function of Bmi1. Several recent reports showed
that Bmi1 is essential for the self-renewal of both hematopoi-
etic and neuronal stem cells as well as cancer stem cells
(11,18–20). This function of Bmi1 depends on its ability to
repress the INK4A-locus. Consistent with a role of Bmi1 in
*To whom correspondence should be addressed. Tel: +49 6421 2865390; Fax: +49 6421 2865196; Email: lutz@imt.uni-marburg.de
  The Author 2006. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Nucleic Acids Research, 2006, Vol. 34, No. 6 1745–1754
doi:10.1093/nar/gkl119stem cell biology, BMI1 expression in the bone marrow is
strong in undifferentiated precursor cells but gradually
declines in the course of differentiation (21). This expression
pattern distinguishes BMI1 from most other PcG genes, whose
expression increases during differentiation of hematopoietic
cells. Despite these important functions little is known about
the transcriptional regulation of the BMI1 gene. The only
transcription factor known to regulate BMI1 expression is
the sonic hedgehog-activated Gli1 protein (22). Whether
this regulation is direct is not known.
Neuroblastomaisanearly childhoodtumorofthe peripheral
nervous system developing from an as yet undeﬁned popula-
tion of neural crest derived cells [reviewed in (23)]. Several
observations, including the early onset of the disease and the
potential of some neuroblastoma cell lines to differentiate into
several distinct cell types in vitro, point to neuroblastoma as a
disease of neural crest derived stem cells (24–26). Several
genetic changes including ampliﬁcation of the MYCN gene
are used to predict neuroblastoma progression and outcome
(27). In contrast, the events that initiate neuroblastomas are
unknown.
E2F transcription factors control several distinct genetic
programs including cell cycle progression and apoptosis
(28–30). E2F-activity is controlled by the retinoblastoma path-
way, which is deregulated in the majority of human cancers. In
neuroblastomas, E2F proteins regulate the expression of the
MYCN gene, which is the single most important molecular
marker of a subset of aggressive neuroblastomas (31).
Recently, expression of the mitotic checkpoint gene MAD2,
also a direct target gene of E2F, was shown to closely correlate
with poor prognosis in neuroblastoma patients, suggesting that
E2F-activity and strong expression of E2F-regulated genes,
respectively, may predict outcome (32).
Here we show that the oncogeneBMI1 isa direct target gene
ofE2F-1.In addition, we show thatBmi1isstronglyexpressed
in primary neuroblastomas. These data provide a novel link
between E2F and polycomb group proteins and suggest a role
of Bmi1 in neuroblastomas.
MATERIALS AND METHODS
Cell culture
Neuroblastoma cells were cultured as described (33). Primary
mouse embryo ﬁbroblasts were isolated from day E13.5
embryos and cultured in DMEM medium containing 10%
fetal calf serum (FCS). Drugs were added to the cell culture
medium at the following concentrations: 4-OHT: 200 nM;
G418: 200 mg/ml. cycloheximide (ICN Biomedicals, Cat. #
194 527): 20 mg/ml; the inhibitory effect on protein synthesis
of the batch of cycloheximide used was tested in a parallel
experiment by measuring the inhibition of
13C-Methionine
incorporation. 1A3 is a clone of SK-N-SH-EP neuroblastoma
cells stably expressing an E2F-1-ER fusion protein (34).
Cell synchronization and flow cytometry
1A3 cells and mouse embryo ﬁbroblasts were starved in serum
free medium for 42 and 36 h, respectively, and then stimulated
to re-enter the cell cycle with 10% FCS. At different times
cells were harvested for isolation of RNA or ﬁxed and stained
with propidium iodide for analysis of cell cycle distribution
using a FACS Calibur.
Plasmids, transfection and reporter assay
For cloning of the luciferase reporter constructs an 816 bp
NotI-fragment of the human BMI1 gene was isolated from
the BAC-clone RP11-232K21 (obtained from the German
Resource Center for Genome Research, Berlin) and inserted
into NotI-digested pBluescript. From there the promoter frag-
ment was transferred as a SacI/XhoI-fragment into
pGL3-Basic resulting in pGL3-BMI1wt. To obtain pGL3-
BMI1mut clustered point mutations were introduced into
the putative E2F binding site using the QuikChange Site-
Directed Mutagenesis Kit and primers that create a novel
NheIrestrictionsite.Cellswere transfectedinDMEMmedium
using calcium phosphate precipitation. The reporter assays
were performed as described (31). The following amounts
of plasmids were co-transfected: 2.5 mg pCMV-eGFP,
2.5 mg pCMV-lacZ, 2.5 mg each of pCMV-E2F-1 and
pCMV-DP1 and 6 mg of pGL3-BMIwt or pGL3-BMImut.
cDNA microarray experiments and statistical analysis
The procedure has been described in detail (35). Brieﬂy, total
RNA was prepared from untreated and drug-treated cells using
the RNeasy Kit (Quiagen). An aliquot of 40 mg of RNA was
used to synthesize Cy3- and Cy5-labeled cDNAs. The
microarray used contained a total of 11 500 sequence-veriﬁed
UniGene cDNAs (Research Genetics, Huntsville, Alabama).
The labeled cDNAs were hybridized to two microarrays sim-
ultaneously. A ﬂip colour experiment was performed with
RNA from an independent experiment. The procedure used
to control the quality of the primary data and the details of the
statistical analysis have been described (35).
Quantitative RT–PCR
Total cytoplasmic RNA was isolated with the RNeasy Kit
(Qiagen) or Trizol Reagent, and 1 mg was reverse transcribed
using MoMuLV Reverse Transcriptase and random primers.
An amount of cDNA ﬁrst strands corresponding to 50 ng of
total RNA was used as template for PCR ampliﬁcation on an
ABI7000 in the presence of SYBR Green. All ampliﬁcations
were performed using a two-step temperature proﬁle with
annealing and extension at 60 C. Differences are either
presented as the difference in threshold cycle numbers
between different samples or were calculated according to
the DDCt relative quantitation method using the S14 gene
encodingaproteinofthe smallribosomalsubunitascalibrator.
(Applied Biosystems User Bulletin #2). The primers used are
listed in Table 1.
Chromatin immunoprecipitation
The details of the chromatin immunoprecipitation assay have
been described (31,34). PCR products were directly quantiﬁed
on an ABI7000 using SYBR Green with all PCRs run in
duplicate. Fold enrichment of the BMI1 promoter sequence
in chromatin immunoprecipitated with different antibodies
was calculated with the DDCt method using the input samples
as reference and the sample without antibody as calibrator.
The following antibodies were used: a-Gadd-45 (sc-H165;
Santa Cruz); a-diacetylated histone H3 (06-599, Upstate
1746 Nucleic Acids Research, 2006, Vol. 34, No. 6Biotechnologies), a-acetylated histone H4 (06-866, Upstate
Biotechnologies); the antibodies speciﬁc for E2F family
members and pocket proteins have been used for chromatin
immunoprecipitation experiments before (31). The primers for
p107 (36) and the ALU repeat sequence (37) have been
described. The primers for BMI1 anneal downstream of the
transcription start site in the ﬁrst exon and had the sequences:
50-CCACTGGCCTGACTACACCGACAC-30 and 50-CGCC-
CCGATCTCTGCCTCTCATAC-30. The control primers
annealing in the ﬁrst intron of BMI1 had the sequences: 50-
AGCCCCCACCCCAGACTTTC-30 and 50-TCAGATCGG-
AATCAGTTCTACCAA-30.
Retroviral infection
Human IMR-32 neuroblastoma cells expressing the ecotropic
receptor were infected with retroviruses based on pBABE-
hygro as has been described (31). RNA was isolated from
infected cells immediately after selection with hygromycin.
Protein analyses
Neuroblastoma tissue was lysed as described before (38).
Cultured cells were lysed by three rounds of freeze/thaw in
a buffer containing 50 mM Tris (pH 8), 150 mM NaCl, 1%
Triton X-100, 1 mM DTT and a cocktail of protease inhibitors.
For cell fractionation, cells were lysed in hypotonic buffer.
After removal of the supernatant containing cytosolic proteins,
nuclei were extracted with 400 mM NaCl. The following
antibodies were used for immunblotting: a-Cdk2 (Santa
Cruz, sc-163), anti-b-Actin (Sigma, clone AC-15), anti-b-
Tubulin (Chemicon, MAB3408), a-Bmi1 (Upstate Biotechno-
logy, clone F6). The chromatin-binding assay was performed
according to a published procedure (39).
RESULTS
Novel E2F-1 target genes in neuroblastoma cells
We have previously identiﬁed the MYCN oncogene as a tissue-
speciﬁc target gene of E2F in neuroblastomas (31). To search
for additional oncogenic target genes of E2F-1 we used 1A3
cells, a derivative of the human neuroblastoma cell line SK-N-
SH-EP constitutively expressing an E2F-1-ER fusion protein
that can be reversibly activated by 4-OHT (34). Upon addition
of 4-OHT 1A3 cells rapidly induce known E2F target genes,
suchasCCNE1(cyclinE)(34).Labeled cDNAs were prepared
from RNA of cells cultured with and without 4-OHT for 12 h
and hybridized to cDNA-microarrays representing 11500
human genes. Statistical analyses of the microarray data iden-
tiﬁed 234 genes that were upregulated and 75 genes that were
downregulated in 4-OHT treated cells (see Supplementary
Data). Less than 2% of these genes responded to treatment
with 4-OHT in parental SK-N-SH-EP cells (Supplementary
Figure 1). Of the genes with a functional annotation 79 have
been described as E2F-1 target genes in U2OS cells (40). To
verify the microarray data we performed RT–PCR on nine
genes that had not been previously described as E2F target
genes. We deliberately included genes that showed a less than
4-fold change in expression in response to E2F-1. Differential
expression was conﬁrmed for eight of these nine genes.
A majority of these genes contain putative E2F binding
sites in their promoters (Table 2). According to DAVID
(GOCharts, classiﬁcation type: biological process, level 5)
(41), 10% of the annotated, E2F-1-responsive genes function
as regulators of transcription (Table 2 and data not shown).
These genes included BMI1, TRIP-Br2 encoding a transcrip-
tional co-regulator of E2F (42), and RYBP. RYBP encodes
a repressor protein that can interact with both E2F and the
polycomb protein Ring-1 (43,44) and is associated with a
mammalian Bmi1-containing complex (6,45).
The polycomb group gene BMI1 is regulated by E2F-1
To verify regulation of BMI1 by E2F-1, RT–PCR was per-
formed with RNA from 1A3 cells that had been cultured with
4-OHT for various times (Figure 1A). BMI1 was induced more
than 10-fold by activated E2F-1-ER. The induction was as
rapid as that of CCNE1. The increase in BMI1 mRNA was
paralleled by an increase in Bmi1 protein (Figure 1B). An
induction of BMI1 by E2F-1 was also seen in Rat1 ﬁbroblasts
Table 1. Sequences of primers used for RT–PCR
Gene Forward primer (50–30) Reverse primer sequences (50–30)
BMI1 AATTAGTTCCAGGGCTTTTCAA CTTCATCTGCAACCTCTCCTCTAT
rat/mouse BMI1 AATTAGTCCCAGGGCTTTTCAA TCTTCTCCTCATCTGCAACTTCTC
mouse ccna2 GCCTTCACTCATTGCTGGAG TGTTGTGCCAATGACTCAGG
CCNE1 AGACGGGGAGCTCAAAACTG TCGTCCACCAGGGCACCAT
mouse ccne1 CTGAGAGATGAGCACTTTCTGC TGGAGCTTATAGACTTCGCACA
EED TGCGCCGGCGGGAACAGACAT TTTCCCTTTCCCCAACTTTTCCTT
EZH2 ACGGGGATAGAGAATGTGGGTTTA AGGTGGGCGGCTTTCTTTATCATC
FHL1 GGAGGACTTCTACTGCGTGAC CTGCCCAGCCAGCTTCTTAGA
HPC2 TCGCGGTGGAGAGCATCGAGAAGA AGCTGCTCCTGCCGTTCCCTGTTC
MEL18 TGGGGATGGGGACAAAGAGAAAAC TCCGCCGCCAGGGGTAGAT
PKNOX1 CACAGGGCTCTGAAGGCACAA ATGAATGCGCAAAACCTGGATTG
PRDM2 GGCACCCACTTGGGACATCTG CCGCCACAGGCTCAGTAGT
RCOR TTGGCATGTTGGTCTGGTCAC TTTTCTTTGGCAATGGCAATGTAT
RING1a GGGGGTGCCGGAGGAGGTG CCAGGGTCAGCGAGCCATTCAAC
RYBP GGTTTTGGGATTGTAGCGTCTG GGGTGGTGGGGTGGCATACT
SOX2 GCCGCCCCCAGCAGACTTC ACCCCTCCCATTTCCCTCGTT
TRIP-Br2 CCCTCCTGATGCGTTAGTTC GGCCTGTGGTTATAGAGTTTC
ZNF22 CCCAGCGAGCCAGAGTGG CTTGGCTTGAGCTCCGAGAA
Nucleic Acids Research, 2006, Vol. 34, No. 6 1747and NIH3T3 cells (Figure 1B). EEDandEZH2,two PcG genes
that encode components of the PRC2 complex and were
described previously as E2F target genes in osteosarcoma
cells (40,46), were induced by E2F-1 also in neuroblastoma
cells (Figure 1C). In contrast, expression of HPC2 and
RING1a, two PcG proteins that like Bmi1 are components
of PRC1, was not affected by E2F-1. Likewise, expression
oftheBmi1homologueMel18,whichsynergizeswith Bmi1to
repress HOX gene clusters during development (47), but in
contrast to Bmi1 represses self-renewal of hematopoietic stem
cells (48), was not changed by E2F-1. Thus, beside compon-
ents of PRC2, E2F-1 speciﬁcally increases expression of Bmi1
but not other proteins of the PRC1 complex.
BMI1 is a direct target gene of E2F-1
To analyze whether the induction of BMI1 by E2F-1 was
direct, cells expressing E2F-1-ER were treated with 4-OHT
in the presence of the protein synthesis inhibitor cyclohexim-
ide. Cycloheximide did not interfere with the activation of
BMI1 indicating that protein biosynthesis is not required for
the induction of BMI1 by E2F-1 (Figure 2A). Indeed, the
promoter of the human BMI1 gene contains a putative E2F
binding site whose sequence and position is conserved in the
mouse gene (Figure 2B). A luciferase reporter gene under
control of 600 bp of the human BMI1 gene including the
putative E2F binding site was activated 7-fold by co-expressed
E2F-1 in neuroblastoma cells (Figure 2C). The reporter gene
was also activated by E2F-2 and E2F-3, but not by E2F-4 and
E2F-5, which where expressed at similar levels (Figure 2C
and data not shown). In contrast, a reporter construct with
a mutated E2F binding site did not respond to E2F-1
(Figure 2D). Moreover, the mutant reporter construct showed
less than 30% of the activity of the wild-type construct in the
absence of ectopic E2F, suggesting that the E2F binding site is
required for full promoter activity.
E2F-1 binds to the BMI1 promoter in vivo
Chromatin immunoprecipitation with an E2F-1 speciﬁc
antibody demonstrated 4-OHT-dependent binding of the
E2F-1-ER fusion protein to the BMI1 promoter in 1A3 cells
(Figure 3A). In addition, endogenous E2F-1 binds to the BMI1
promoter in SK-N-SY5Y neuroblastoma cells that strongly
express BMI1 (Figure3B).Binding of E2F-1 was alsodetected
at the promoter of the p107 gene, a well-known target gene of
E2F-1, but not at the ﬁrst intron of BMI1 4 kb downstream
of the promoter and at an ALU repeat sequence used as a
Table 2. E2F-1 regulated genes
Gene
symbol
Accession
number
Description Up/ down Fold change
(array)
Fold change
(RT–PCR)
E2F site (position)
RYBP AA454193 RING-1 and YY1 binding protein up 5.0 5.3 —
ZNF22 R37224 Zinc finger protein 22 (KOX 15) down 4.9 10.6 TCTGGCGC ( 30)
PKNOX1 H77399 PBX/knotted 1 homeobox 1 up 4.8 5.7 GTTCCCGC ( 120)
TGTGCCGC ( 520)
RCOR AA457026 REST corepressor up 4.5 4.6 —
BMI1 AA478036 Bmi1 up 4.1 8.6 TGTGGCGC ( 320)
FHL1 AA455925 Four and a half LIM domains 1 up 4.1 3.7 TCTCCCGC ( 180)
TRIP-Br2 AA489659 Transcriptional co-regulator up 3.9 2.3 TATCGCGC ( 130)
PRDM2 W73060 RIZ1, histone methyltransferase up 3.8 9.2 —
Figure 1. E2F-1activatestheBMI1gene.(A)RapidinductionofBMI1mRNA
in response to activated E2F-1. 1A3, a clone of the human neuroblastoma cell
line SK-N-SH-EP expressing an E2F-1-ER fusion protein, was cultured with
4-OHT for various times. RNA was isolated, reverse transcribed and used for
quantitative PCR. The CCNE1 gene was used as a positive control. (B) E2F-1
increases Bmi1 protein levels. 1A3 cells and Rat1 cells stably expressing
E2F-1-ER and NIH3T3 cells infected with a retrovirus carrying E2F-1-ER
were treated with 4-OHT or ethanol for 15 h. Bmi1 was detected in cell lysates
by immunoblotting. Antibodies specific for Cdk2 or b-Tubulin were used to
control for equal loading. (C) Not all PcG genes are regulated by E2F-1. 1A3
cells were treated with 4-OHT or the solvent control ethanol for 12 h and then
analyzed by RT–PCR.
1748 Nucleic Acids Research, 2006, Vol. 34, No. 6negative control (Figure 3B). In line with the reporter assays
we also observed binding of endogenous E2F-2, E2F-3 and to
a much lesser extent E2F-4 to the BMI1 promoter (Figure 3B).
E2F-1 recruits several histone acetyltransferases leading to the
rapid acetylation of histones H3 and H4 at target promoters
(49). Consistent with transcriptional activation of the BMI1
gene by E2F-1-ER, acetylation of histone H4 was strongly
increased at the BMI1 promoter after activation of E2F-1
(Figure 3C). There was no change in the acetylation of histone
H3, which was already acetylated prior to activation of
E2F-1-ER by 4-OHT. In summary, we concluded that
BMI1 is regulated by E2F-1 via direct binding of E2F-1 to
the BMI1 promoter.
E2F-1 induced Bmi1 is associated with chromatin
Bmi1 acts as a subunit of nuclear multiprotein complexes that
associate with chromatin. Consistent with this, in untreated
1A3 cells almost all Bmi1 was detected in the nuclear
fraction and only very little in the cytosolic fraction
(Figure 4A). After activation of E2F-1-ER, Bmi1 was still
almost exclusively localized in the nucleus. To show associ-
ation of Bmi1 with chromatin we performed a chromatin-
binding assay (39). After mild cell lysis, nuclei were collected
and were either left untreated or were incubated with micro-
coccal nuclease to solubilize speciﬁcally chromatin-bound
proteins but not nuclear matrix-bound proteins. The samples
were then centrifuged to separate soluble and insoluble pro-
teins. Without nuclease treatment only a small fraction of
Bmi1 was detected in the soluble nuclear fraction of both
untreated and 4-OHT treated cells (Figure 4B). Treatment
of the nuclei with micrococcal nuclease solubilized a large
amount of Bmi1 protein in both treated and untreated cells.
Together, these data show that the increased amount of
Bmi1 protein produced in response to E2F-1 associates
with chromatin.
Figure 2. BMI1 is a direct target gene of E2F-1. (A) Protein synthesis is not required for induction of BMI1 by E2F-1. 1A3 cells were treated for 16 h with
cycloheximide (CHX) and for 10 h with 4-OHT and then analyzed by RT–PCR. (B) The human BMI1 promoter contains a putative E2F binding site. Shown are
theBMI1promoter-dependentreporterconstructsusedandthelocationandsequenceoftheputativeE2Fbindingsite.Thearrowatposition+1marksthe50 endofthe
published cDNA sequence. The transcription start site has not yet been experimentally defined. Thus, the E2F binding site may be positioned closer to the
transcriptionstartsitethanindicated.(C)E2F-1,E2F-2andE2F-3activateBMI1throughabindingsiteintheproximalpromoter.SK-N-SY5Yhumanneuroblastoma
cellsweretransientlyco-transfectedwithaBMI1promoter-controlledreporterconstructandeitheremptyvectororexpressionvectorsfordifferentE2Fproteinsand
the dimerization partner DP1. Error bars represent the standard deviation obtained with triplicate samples. (D) E2F-1 activates BMI1 through a binding site in the
proximalpromoter.SK-N-SY5Yhumanneuroblastomacellsweretransientlyco-transfectedwithwild-typeormutatedreporterconstructsandeitheremptyvectoror
expression vectors for E2F-1 and DP1. Error bars represent the standard deviation obtained with triplicate samples.
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cell cycle or differentiation
E2F-1 can induce several distinct genetic programs including
the progression of cells into the S phase of the cell cycle.
Consequently, many E2F target genes are expressed in a
cell cycle-regulated manner. To see whether BMI1 expression
changes during the cell cycle serum-starved 1A3 cells were
stimulated with 10% FCS to synchronously re-enter the cell
cycle. At various times after serum stimulation mRNA was
isolated to measure by RT–PCR the expression of different
E2F-1 target genes. Compared to serum-starved cells the
expression of CCNE1 was increased more than 4-fold after
7 h of serum stimulation and remained elevated thereafter
(Figure 5A). In contrast, the amount of BMI1 mRNA did
not change during the experiment. The levels of BMI1
RNA were alsomeasuredinprimarymouseembryoﬁbroblasts
(MEFs) that had been arrested by serum starvation and then
stimulated with mitogens (Figure 5B). Expression of Ccne1
and CcnaA2 (cyclin A2) increased 12 and 16 h, respectively,
after serum addition. Again, the levels of BMI1 mRNA
remained unchanged. A recent report applying ChIP on
chip technology provided evidence that in T98G and U2OS
cells arrested by removal of growth factors, contact inhibition
or overexpression of the Cyclin-dependent kinase inhibitor
p16Ink4a, E2F-4 and the pocket protein p130 are associated
with the BMI1 promoter, suggesting that BMI1 expression is
repressed in these cells under conditions of growth arrest (50).
Figure 3. E2F-1bindstotheBMI1promoterinvivo.(A)E2F-1-ERbindstotheBMI1promoteruponactivationby4-OHT.Crosslinkedchromatinwasisolatedfrom
untreated and 4-OHT treated 1A3 cells and precipitated with an E2F-1 specific antibody or a control antibody. The precipitated chromatin was used as template for
PCR. (B) Endogenous E2F proteins bind to the BMI1 promoter in vivo. Crosslinked chromatin was isolated from SK-N-SY5Y human neuroblastoma cells and
precipitatedeitherwithantibodiesspecificfordifferentE2Fproteins,anunrelatedcontrolantibody,orproteinA/G-sepharosewithoutantibody.Asapositivecontrol
weusedprimersthatamplifytheproximalpromoteroftheE2Ftargetgenep107.Aprimerpairthatamplifiesasequenceatthe30 endofthefirstintronofBMI14kb
downstreamoftheE2FbindingsiteandaspecificALUrepeatsequencelocatedwithinheterochromatinwereusedasnegativecontrols.Thebarsrepresentenrichment
of the BMI1 promoter sequence relative to the control sample precipitated without antibody. (C) E2F-1-ER induces acetylation of histone H4 but not histone H3 at
theBMI1promoter.Chromatinfromuntreatedand4-OHTtreated1A3cellswasprecipitatedwithantibodiesspecificforacetylatedhistonesH3andH4andanalyzed
by PCR.
1750 Nucleic Acids Research, 2006, Vol. 34, No. 6Using the same approach binding of E2F-4 and pocket
proteins to the BMI1 promoter was also observed in cycling
cells in early G1 phase (51). Yet, similar to the situation in
neuroblastoma cells and primary MEFs BMI1 expression was
not reduced in growth-arrested versus proliferating T98G
cells (data not shown). Consistent with a lack of cell cycle
regulation, the overexpression of p16Ink4a, which blocks
activation of cell cycle-regulated E2F target genes by
inhibiting Cyclin-dependent kinases, resulted in down-
regulation of CCNE1 but not BMI1 (Figure 5C).
E2F proteins have recently been implicated in the control
of gene expression during development and differentiation
(52–54). The BMI1 gene is shut-off during differentiation in
several cell lineages (21,22). We therefore measured the
expression of BMI1 in LA-N-5 neuroblastoma cells before
and after neuronal differentiation. LA-N-5 cells treated with
pharmacological concentrations of all-trans retinoic acid
ceased proliferation and within 10 days aggregated into
pseudoganglia that were interconnected by a network of
long axon-like processes (data not shown). Despite these
extensive morphological changes, the expression of BMI1
did not change (data not shown). We concluded that BMI1
is not regulated in a differentiation-dependent manner in
neuroblastoma cells.
Bmi1 is expressed in primary neuroblastomas
The events thatinitiateneuroblastoma are still unknown.Since
E2F-regulated genes are disproportionately overexpressed in
many types of cancer including neuroblastoma, and since the
expression of several E2F target genes correlates with poor
outcome in neuroblastoma (32,55) we measured Bmi1 protein
levels in 68 primary neuroblastomas of different tumor stages
and MYCN status. Previous histochemical analyses showed
that these tumors contain less than 5% nontumor cells (35).
Strong Bmi1 expression similar to the expression seen in the
neuroblastoma cell line SK-N-SH-EP was detected in
more than 90% of these tumors regardless of tumor stage
and MYCN status (Figure 6A and B and data not shown).
Figure 4. E2F-1 induced Bmi1 binds to chromatin. (A) E2F-1 induced Bmi1
localizes to the nucleus. 1A3 cells were treated for 12 h with 4-OHT or the
solventcontrolethanol.Cellswerethenseparatedintocytosolic(C)andnuclear
(N) fractions and analyzed by immunoblotting. (B) E2F-1 induced Bmi1 is
associated with chromatin. Nuclei of untreated and 4-OHT treated cells were
incubated with micrococcal nuclease (MN) to solubilize specifically
chromatin-bound proteins. Bmi1 protein in the different fractionswas detected
by immunoblotting.
Figure 5. Expression of BMI1 is not cell cycle-regulated. (A) 1A3 cells were serum-starved for 42 h and then stimulatedto re-enter the cell cycle by the addition of
10% FCS. At various time points cells were harvested for RT–PCR and analysis of the cell cycle distribution by propidiumiodide staining and flow cytometry. The
bars indicate the fold change in mRNA levels relative to starved cells for the indicated E2F-1 target genes. (B) Primary mouse embryo fibroblasts were treated and
analyzed as described in Figure 5A except that primers specific for the mouse genes were used. (C) Overexpression of p16Ink4a does not affect BMI1 expression.
IMR-32 human neuroblastoma cells expressing the ecotropic receptor were infected with a retrovirus carrying the INK4a gene or an empty control virus. RNA was
prepared from pools of infected cells that had been selected with hygromycin and used for RT–PCR.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1751We have previously shown that E2F-activity is required but
not sufﬁcient for full expression of MYCN in neuroblastomas,
providing an explanation for why not all tumors that express
BMI1 also express MYCN, although both genes are activated
by deregulated E2F (34).
DISCUSSION
Bmi1 has important functions in embryonic development,
stem cell biology, and cancer. Thus, it is surprising, that
only little is known about the transcriptional regulation of
the BMI1 gene. We show here that the transcription factor
E2F-1 directly regulates BMI1. This is based on the following
observations: (i) E2F-1 activates BMI1 in multiple cell types
from different species. (ii) E2F-1 activates BMI1 in the
absence of protein synthesis and with the same kinetics as
known E2F target genes. (iii) Activation of BMI1 by E2F
requires an evolutionary conserved E2F binding site located
in the proximalpromoter. (iv) Endogenous E2F-1 is associated
with the BMI1 promoter in cancer cells.
However, BMI1 is not expressed in a cell cycle-regulated
manner in various primary and transformed cells and is not
affected by overexpression of p16Ink4a. Thus, BMI1 is not a
classical E2F target gene. Indeed, in recent years numerous
genes have emerged that are regulated by E2F in a cell
cycle-independent manner (52,56). Several observations
indicate a role of E2F in development, and induction of
BMI1 may be related to one of these developmental functions
(52–54). For example, in Drosophila, E2F acts as a suppressor
of position effect variegation, indicating an epigenetic inﬂu-
ence of E2F on developmental processes (57).
Alternatively, induction of BMI1 by activating E2Fs may be
restricted to cells with deregulated E2F as has been shown for
other E2F target genes, such as ARF (Aslanian 2004). Indeed,
overexpression of BMI1 has been found in various types of
cancer (11–15). Bmi1 can co-operate with the Myc oncopro-
tein in the generation of lymphomas in double transgenic mice
(58). The mechanism of this co-operation is the ability of
Bmi1 to repress Myc-induced apoptosis (58). The N-Myc
protein is known to sensitize neuroblastoma cells to multiple
apoptotic stimuli (59,60). Thus, in a manner analogous to its
role in lymphomas, Bmi1 may pave the way for MYCN
ampliﬁcation in neuroblastoma cells by blocking N-Myc-
induced apoptosis. As both MYCN and BMI1 are direct targets
of E2F-1 in neuroblastoma cells, uncontrolled activity of E2F
may have fatal consequences by inducing the expression of
two co-operating oncogenes. Once activated, two positive
feedback loops will keep E2F, Bmi1 and N-Myc active.
Firstly, E2F not only induces MYCN, but also Myc in turn
can stimulate E2F-activity (61,62). Secondly, Bmi1 represses
the INK4A gene thereby promoting phosphorylation of the
retinoblastoma protein and activation of E2F (58). Based on
the known functions of E2F, Bmi1 and N-Myc this network
of oncogenic transcription factors could be instrumental in
initiating and maintaining neuroblastomas.
Our cDNA microarray analysis of neuroblastoma cells
expressing a conditional form of E2F-1 identiﬁed a large
number of hitherto unknown E2F-1 target genes beside
BMI1. This is surprising given that several comprehensive
searches for E2F target genes have already been published,
resulting in the identiﬁcation of hundreds of E2F target genes
(40,63–66). These previous studies have been performed in
ﬁbroblasts and osteosarcoma cells that are very different from
neuroblastoma cells in terms of ontogenetic history and func-
tion. We predict that some of the genes in our list are tissue-
speciﬁc target genes of E2F-1 that adjust the E2F-regulated
genetic program to the needs of particular cell types as has
been shown previously for MYCN and PPARg (31,53). In fact,
a number of studies in mice and ﬂies have revealed tissue-
speciﬁc functions for E2F proteins (52,67).
Strikingly, many of the E2F-1 regulated genes with a func-
tional annotation identiﬁed in our screen function primarily in
transcriptional regulation. This suggests that the primary
response of cells to activated E2F-1 is followed by a complex
secondary response based on gene expression changes
triggered by dozens of E2F-regulated transcription factors.
Several of these transcriptional regulators have already been
linked to E2F function. For example, Rybp and Trip-Br2 can
both function as co-regulators of E2F (42,44). Thus, E2F-1
induces some of the very co-factors it uses for the control of
target genes, creating so-called feedforward-loops (68).
In contrast to PRC2, of which several subunits are coordin-
ately induced by E2F-1 (40,46), Bmi1 appears to be the only
subunit of the PRC1 complex to be regulated by E2F-1.
Neither Mel18 nor Hpc2, which is an essential component
of a polycomb complex that interacts with the retinoblastoma
Figure 6. Bmi1 is strongly expressed in primary neuroblastomas. (A) Bmi1
levels in primary neuroblastomas. Shown is a representative immunoblot
detection of Bmi1 in lysates of primary neuroblastomas of different tumor
stages including two of the tumors that were scored as negative for Bmi1
expression. Bmi1 expression in the neuroblastoma cell line SK-N-SH-EP is
shown for comparison. b-Actin was used as a loading control. (B) Summary of
theimmunoblotresultsfor68primaryneuroblastomasshowingthenumberand
percentage of Bmi1-positive tumors among tumors of different stages and
MYCN status.
1752 Nucleic Acids Research, 2006, Vol. 34, No. 6protein to induce an HDAC-independent cell cycle arrest (69),
nor Ring1a were induced by E2F-1. It has been proposed that
the relative amounts of Bmi1 and Hpc2 in the complex deter-
mine the biochemical and biological functions of the complex
(69). According to this model, the Bmi1-enriched complex
would favor proliferation by repressing the INK4A-locus,
while the Hpc2-dominated complex would arrest cells by
repressing a subset of E2F-regulated genes. If true, the select-
ive induction of BMI1 by E2F-1 would change the com-
position of the polycomb complex to favor proliferation
over cell cycle arrest.
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